GE Healthcare invests in cardiac diagnostics
This article was originally published in The Gray Sheet
Firm's "Healthymagination Fund" enters into a $5 million strategic alliance with CardioDx to co-develop diagnostics for cardiovascular disease, GE announces May 13. CardioDx's flagship product, Corus CAD, a non-invasive genomic test to assess the potential for coronary artery disease, launched in the U.S. last fall (1"The Gray Sheet" Sept. 7, 2009). The deal marks the $250 million Healthymagination Fund's first investment since its formation in October 2009 (2"The Gray Sheet" Nov. 2, 2009). The equity fund targets three broad areas for investment: diagnostics, health care information technology and life sciences
You may also be interested in...
CardioDx is gradually rolling out its Corus CAD gene expression test, which quantifies the likelihood of obstructive coronary artery disease in patients with stable chest pain and no previous history of cardiac disease
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.